Format

Send to

Choose Destination
Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Author information

1
The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: Thomas.Powles@bartshealth.nhs.uk.
2
Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
3
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
4
Department of Urology, University of Rennes, Rennes, France.
5
Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
6
Patient Advocacy, International Kidney Cancer Coalition, Duivendrecht, The Netherlands; University Medical Center Utrecht, Department of Nephrology and Hypertension, Regenerative Medicine Center Utrecht, University of Utrecht, The Netherlands.
7
Department of Urology, Sunderby Hospital, Sunderby, Sweden.
8
Faculty Hospital Plzeň and Faculty of Medicine in Plzeň, Charles University, Czech Republic.
9
Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
10
Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
11
Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
12
Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
13
Department of Urology, Cabueñes Hospital, Gijón, Spain.
14
Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
15
Division of Urology, Maggiore Della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
16
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
17
Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Abstract

The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated.

PATIENT SUMMARY:

The European Association of Urology guidelines will be updated based on the results of the phase III Checkmate-214 clinical trial. The trial showed superior survival for a combination of ipilimumab and nivolumab (IN), compared with the previous standard of care, in intermediate- and poor-risk patients with metastatic clear cell renal cell carcinoma. When IN is not safe or feasible, alternative agents such as sunitinib, pazopanib, and cabozantinib should be considered. Furthermore, at present, the data from the trial are immature in favourable-risk patients. Therefore, sunitinib or pazopanib remains the favoured agent for this subgroup of patients.

KEYWORDS:

European Association of Urology guidelines; Ipilimumab; Nivolumab; Renal cell carcinoma

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center